CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Regeneron Pharmaceuticals, Inc. vs. Novartis Pharma AG et al.

Explore the PTAB proceeding IPR2020-01317 filed by Regeneron Pharmaceuticals, Inc. on 2020-07-16. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2020-01317

Filing Date

2020-07-16

Accorded Filing Date

2020-07-16

Institution Decision Date

2021-01-15

Last Modified Date

2022-10-10

Proceeding Type

IPR

Termination Date

โ€”

Trial Status

Institution Denied

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 13750352
Respondent Patent Number 9220631
Legal Expiration Date
2033-01-25 Active (6.2 yrs remaining)
Injunction Viability (35 U.S.C. ยง 283) Active Threat
Respondent Inventor Juergen Sigg et al
Respondent Tech Center TC 3700 - Mechanical Engineering & Manufacturing

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 3700 - Mechanical Engineering & Manufacturing

Decisions Rendered

0 Total

Proceeding Status

Institution Denied

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Address and Attorney/Agent Information

32 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name NOVARTIS PHARMACEUTICAL CORPORATION - INTELLECTUAL PROPERTY DEPARTMENT
Customer Number 1095
Address 250 Massachusetts Avenue, Cambridge, MA, 02139, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
39030 Jean Silveri +1 617-871-5134
40232 Timothy Witkowski +1 617-301-1869
43228 Peter Waibel +1 862-778-7838
46473 Emily Wu +1 858-812-1539
46593 Laurie Lawrence +1 617-871-8584
48631 Carol Fang +1 650-467-2901
51681 Mark Flanigan +1 817-615-5080
53504 Daniel Raymond +1 858-812-1617

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials 2 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): ๐Ÿ‡ฉ๐Ÿ‡ช Germany ๐Ÿ‡ช๐Ÿ‡บ Europe ๐Ÿ‡บ๐Ÿ‡ธ US
Parallel Proceedings Across Jurisdictions (2 found):
PTAB: 2
USPTO PTAB Trial 2021-04-16
IPR2021-00816

Regeneron Pharmaceuticals, Inc. et al. v. Novartis Pharma AG et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2020-07-16
IPR2020-01318

Regeneron Pharmaceuticals, Inc. et al. v. Novartis Pharma AG et al.

Asserted Patent
Status: Terminated
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Proceeding Documents

155
22

Notice of Refund Paper

2021-06-01 FILING PARTY: BOARD
21

Petitioner's Request for Refund of Post-Institution Fees Paper

2021-05-18 FILING PARTY: PETITIONER
20

ORDER Conduct of the Proceeding 37 C.F.R. ๏ฟฝ๏ฟฝ๏ฟฝ๏ฟฝ 42.5, 42.20 Paper

2021-05-03 FILING PARTY: BOARD
19

Petitioner๏ฟฝ๏ฟฝ๏ฟฝs Unopposed Motion to Withdraw Its Request for Rehearing of The Board๏ฟฝ๏ฟฝ๏ฟฝs Decision Denying Inter Partes Review Paper

2021-04-27 FILING PARTY: PETITIONER
3004

Ex. 3004 Exhibits

2021-04-22 FILING PARTY: BOARD

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc